Table 1 Clinical characteristics and treatment information of patients.

From: Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer

 Cases%
Patients61100
Age (year)
 <502337.7
 >503862.3
Clinical tumor stage
 T2914.8
 T33659.0
 T41626.2
Clinical nodal status
 Negative711.5
 Positive5488.5
Grade
 IIb2947.5
 III3252.5
Pathological type
infiltrating duct carcinoma5082
infiltrating lobular carcinoma58.2
mucinous adenocarcinoma23.3
squamous carcinoma11.6
medullary carcinoma34.9
HR status
 Positive2947.5
 Negative3252.5
HER2 status
 Positive1931.1
 Negative4268.9
Breast cancer subtypes
 HR+/HER2−1524.6
 HR+/HER2+1423.0
 HR−/HER2+58.2
 TNBC2744.3
Chemotherapeutic scheme
 FEC1729.9
 TE4461.1
Operative method
 No surgery1219.7
 Modified radical surgery1321.3
 radical surgery2744.3
 Extended radical surgery914.7
  1. ER, estrogen receptor; PR, progestin receptor; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; FEC (5-FU 600 mg/m2+ Epirubicin90 mg/m2+ Cyclophosphamide600 mg/m2). TE (Paclitaxel 175 mg/m2+ Epirubicin 90 mg/m2).